NEW YORK – CND Life Sciences said Wednesday it has signed a licensing deal that will advance the company's skin-based neurodegenerative disease test by giving it access to technologies developed at Beth Israel Deaconess Medical Center.
Phoenix-based CND said the agreement with Boston-based Beth Israel gives CND access to technologies important for CND's Syn-One Test, which uses small skin biopsies to identify misfolded phosphorylated alpha-synuclein proteins that are found in cutaneous nerve fibers. Those proteins are hallmarks of the synucleinopathy family of neurogenerative diseases that includes Parkinson's disease and dementia with Lewy bodies. CND launched the test in 2019.
Financial and other terms of the deal were not disclosed.
CND also said it is collaborating with Beth Israel on studies that could identify other protein markers in skin that could help identify neurodegenerative diseases and guide future therapies for conditions including Parkinson's disease and Alzheimer's disease.